Osborn D A, Sinn J
Cochrane Database Syst Rev. 2003(4):CD003664. doi: 10.1002/14651858.CD003664.
Allergies and food reactions are common and may be associated with foods including adapted cow's milk formulas. Formulas containing hydrolysed proteins have been used to treat infants with allergy or food intolerance, and have been advocated for prevention of allergy and food intolerance in infants.
To determine whether use of hydrolysed formulas for infant feeding prevents allergy and food intolerance. If hydrolysed formulas are effective, to determine what type of hydrolysed formula is most effective including extensively and partially hydrolysed formulas. To determine which infants benefit including infants at low or high risk of allergy and infants receiving early, short term or prolonged formula feeding.
The standard search strategy of the Cochrane Neonatal Review Group was used including searches of the Cochrane Controlled Trials Register (2003, Issue 1), MEDLINE (1966 - January 2003), EMBASE (1980 - January 2003) and CINAHL (1982 - January 2003) and previous reviews including cross references.
Randomised and quasi-randomised trials that compare the use of a hydrolysed infant formula to human milk or cow's milk formula. Trials with >80% follow up of participants were eligible for inclusion.
Eligibility of studies for inclusion, methodological quality and data extraction were assessed independently by each reviewer. Primary outcomes included clinical allergy, specific allergies and food intolerance. Meta-analysis was conducted using a fixed effects model.
Eighteen trials met criteria for inclusion. No eligible trials compared prolonged hydrolysed formula to human milk feeding. Two trials compared early, short term hydrolysed formula to human milk feeding and reported no significant difference in infant allergy or childhood cow's milk allergy (CMA). Two trials compared early, short term hydrolysed formula to cow's milk formula feeding with no significant benefits reported. One large quasi-random study reported a reduction in infant CMA of borderline significance in low risk infants (RR 0.62, 95% CI 0.38, 1.00).Seven studies compared prolonged feeding of hydrolysed formula to cow's milk formula without using co-interventions for allergy prevention. Meta-analysis of 4 studies (386 infants) found a significant reduction in allergy incidence in infancy (typical RR 0.63, 95% CI 0.47, 0.85; RD -0.15, 95% CI -0.25, -0.06). One study reported a significant reduction in allergy incidence in childhood (RR 0.54, 95% CI 0.36, 0.81). Significant reductions were found in asthma prevalence in childhood, eczema incidence in infancy and prevalence in childhood, food allergy prevalence in childhood, and CMA incidence in infancy. All studies enrolled infants at high risk of allergy. Only three trials comparing prolonged hydrolysed formula feeding to cow's milk formula feeding were considered of good methodology. Only one of these trials demonstrated a benefit into childhood (5 years of age). No eligible trials examined the effects of prolonged hydrolysed formula feeding on allergy beyond early childhood. Costs were not reported. Three trials compared prolonged feeding with an extensive to a partially hydrolysed formula and reported no significant difference in allergy incidence in infancy.
REVIEWER'S CONCLUSIONS: There is no evidence to support feeding with a hydrolysed formula for the prevention of allergy in preference to exclusive breast feeding. In high risk infants who are unable to be completely breast fed, there is evidence that prolonged feeding with a hydrolysed compared to a cow's milk formula reduces infant and childhood allergy and infant CMA. Further trials are required to determine if significant clinical benefits persist beyond 5 years of age and if there is any additional benefit from use of an extensive compared to a partially hydrolysed formula. Incremental costs of formula and the effect on compliance should be measured.
过敏和食物反应很常见,可能与包括适度水解牛奶配方奶在内的食物有关。含水解蛋白的配方奶已被用于治疗过敏或食物不耐受的婴儿,并被提倡用于预防婴儿的过敏和食物不耐受。
确定使用水解配方奶进行婴儿喂养是否可预防过敏和食物不耐受。如果水解配方奶有效,确定哪种类型的水解配方奶最有效,包括深度水解配方奶和部分水解配方奶。确定哪些婴儿会从中受益,包括过敏低风险或高风险的婴儿,以及接受早期、短期或长期配方奶喂养的婴儿。
采用Cochrane新生儿回顾组的标准检索策略,包括检索Cochrane对照试验注册库(2003年第1期)、MEDLINE(1966年至2003年1月)、EMBASE(1980年至2003年1月)和CINAHL(1982年至2003年1月)以及以往的综述,包括交叉参考文献。
比较使用水解婴儿配方奶与母乳或牛奶配方奶的随机和半随机试验。对参与者随访率>80%的试验符合纳入标准。
每位综述员独立评估纳入研究的合格性、方法学质量和数据提取。主要结局包括临床过敏、特异性过敏和食物不耐受。采用固定效应模型进行荟萃分析。
18项试验符合纳入标准。没有符合条件的试验比较长期水解配方奶与母乳喂养。两项试验比较早期、短期水解配方奶与母乳喂养,结果显示婴儿过敏或儿童期牛奶过敏(CMA)无显著差异。两项试验比较早期、短期水解配方奶与牛奶配方奶喂养,未报告有显著益处。一项大型半随机研究报告,低风险婴儿的婴儿CMA有临界显著降低(RR 0.62,95%CI 0.38,1.00)。七项研究比较了长期水解配方奶与牛奶配方奶喂养,未采取预防过敏的联合干预措施。对4项研究(386名婴儿)的荟萃分析发现,婴儿期过敏发生率显著降低(典型RR 0.63,95%CI 0.47,0.85;RD -0.15,95%CI -0.25,-0.06)。一项研究报告儿童期过敏发生率显著降低(RR